Based on the Company's current operating plan, the Company continues to anticipate full-year 2019 operating expenses to range between $130 million and $140 million, before accounting for amounts reimbursable under the Neurocrine
Biosciences collaboration, and anticipates cash, cash equivalents and marketable debt securities at year end of approximately $280 million to $290 million.
Biosciences Inc (NASDAQ: NBIX), a neuroscience-focused, biopharmaceutical company, announced yesterday its financial results for the six months ended 30 June 2019.
Roberts, M.D., Chief Medical Officer, Neurocrine
Biopharmaceutical company Neurocrine
Biosciences Inc (NASDAQ:NBIX) said on Wednesday that it has successfully filed its New Drug Application (NDA) with the US Food and Drug Administration (FDA) for opicapone as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes.
The 2018 Promising Scholars Award Program, jointly sponsored by Neurocrine
Biosciences and the Neuroleptic Malignant Syndrome Information Service (NMSIS), provides a unique opportunity for early-career psychiatrists to gain experience in scholarly activities and research.
[USPRwire, Sun May 24 2015] Global Markets Direct's, 'Neurocrine
Shares of Neurocrine
Biosciences closed the week up 4 cents at $5.74 on Nasdaq.
intends to initiate clinical studies after submission of an investigational new drug application in the first half of 2008.
2006 Looks Good For Teva and Neurocrine
Unlike these agents, which are already on the market, indiplon was designed to have a very short half-life, according to its developer, Neurocrine
Unlike these agents, which are on the market, indiplon was designed to have a very short half-life, according to its developer, Neurocrine
Biosciences Inc., which also claims that indiplon is a more potent binder to the GABA receptor than its two competitor drugs.
(PAV212) GARY LYONS - NEUROCRINE
BIOSCIENCES INC (NBIX).